Drug Profile


Alternative Names: SR 48968

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidepressants; Benzamides; Piperidines
  • Mechanism of Action Neurokinin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Asthma; Generalised anxiety disorder; Inflammatory bowel diseases; Irritable bowel syndrome; Major depressive disorder; Pain

Most Recent Events

  • 29 Apr 2009 Discontinued - Phase-III for Depression in Argentina (PO)
  • 29 Apr 2009 Discontinued - Phase-III for Depression in Chile (PO)
  • 29 Apr 2009 Discontinued - Phase-III for Depression in Croatia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top